METTL3 mediates the progression of diabetic nephropathy through regulating the apoptosis and mitophagy of renal tubular epithelial cells. Mechanistically, METTL3 regulates the m6A modification and expression of PINK1 dependent on YTHDF2. We hope these findings could provide novel targets for the treatment of diabetic nephropathy disease.

The indexes related to the area under the C-peptide curve for six time periods during an oral glucose tolerance test and C-peptide release test might be independent predictors of the incidence of diabetic retinopathy in patients with type 2 diabetes. The area under the C-peptide curve has the added advantage of being a cheap and convenient risk assessment over traditional ophthalmic screening.

In addition to age and diabetes duration, HbA1c variability was identified as a strong predictor for the development of a new DSPN. Among the different measures of HbA1c variability examined, HbA1c ARV showed the greatest potential as a dependable indicator for predicting the onset of new DSPN.

The potential causal relationship between body composition traits and gestational diabetes mellitus (GDM) reminds clinical doctors and nurses to pay attention to the early screening of pregnant women in order to reduce the risk of GDM and other complications. Additionally, further studies are imperative to establish a causal connection between body composition traits and GDM.

The study suggests that lipid profiles differ by ethnic origin in gestational diabetes mellitus, but show a common behavior tendency, resembling what happens in non-diabetic pregnant women, indicating a physiological role of lipoprotein modification occurring during gestation.

A meta-analysis of six observational studies showed that type 1 diabetes may be associated with a higher incidence of epilepsy. The association was consistent in children and the adult population.

This large retrospective cohort study of type 2 diabetes mellitus conducted in Japan, using an administrative database, showed significantly lower numbers of hospitalizations per person per month (PPPM) and outpatient visits PPPM and shorter length of stay per hospitalization in patients newly treated with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) than those newly treated with a dipeptidyl peptidase-4 inhibitor (DPP4i). All-cause overall healthcare costs PPPM and all-cause hospitalization costs PPPM were also generally lower in patients receiving an SGLT2i than those receiving a DPP4i. The results suggest economic benefits with SGLT2i vs DPP4i in the management of type 2 diabetes mellitus.

Patients with type 2 diabetes mellitus complicated by refractory severe asthma were treated with tezepelumab, an anti-thymic stromal lymphopoietin antibody. The requirement of prednisolone due to asthma exacerbation was decreased, but the patient showed worsening of glycemic management, increased insulin requirement and weight gain. When administering tezepelumab to patients with asthma complicating type 2 diabetes, careful follow up regarding glycemic management and weight might be necessary.